CDX 301
Alternative Names: CDX-301; Flt-3 ligand; Flt3-L; Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics; Mobista; rhuFlt3L; Vaccine-adjuvant-Amgen; Vaccine-adjuvant-Celldex-Therapeutics; Vaccine-adjuvant-FLT-3-ligand; Vaccine-adjuvant-ImmunexLatest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Amgen
- Developer Albert Einstein College of Medicine; Amgen; Celldex Therapeutics Inc; Dana-Farber Cancer Institute; Icahn School of Medicine at Mount Sinai; Merck Sharp & Dohme; Washington University School of Medicine
- Class Adjuvants; Antineoplastics; Antiretrovirals; Cytokines; Immunotherapies; Recombinant proteins
- Mechanism of Action Fms-like tyrosine kinase 3 stimulants; Haematopoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Pancreatic cancer
- Phase I/II B-cell lymphoma; Breast cancer; Head and neck cancer; Non-Hodgkin's lymphoma
- Phase I Malignant melanoma; Triple negative breast cancer
- No development reported HIV infections; Lymphoma; Prostate cancer; Solid tumours
- Discontinued Autoimmune disorders; Infections; Stem cell mobilisation
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Prevention) in USA (SC)
- 28 Apr 2024 No recent reports of development identified for preclinical development in HIV-infections in USA
- 21 Nov 2023 Washington University School of Medicine, in collaboration with Celldex Therapeutics and The Foundation for Barnes-Jewish Hospital terminates a phase II trial in Pancreatic cancer (Combination therapy) in USA (IV; infusion) due to Celldex decision (NCT04536077)